Full Press Release Details
updated linvoseltamab bcmaxcd3 data from pivotal trial demonstrates early deep and durable responses in patients with heavily pre treated multiple myeloma.
REGN
updated linvoseltamab bcmaxcd3 data from pivotal trial demonstrates early deep and durable responses in patients with heavily pre treated multiple myeloma
Key Takeaway: updated linvoseltamab bcmaxcd3 data from pivotal trial demonstrates early deep and durable responses in patients with heavily pre treated multiple myeloma